US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

13.99

+0.42003.10%

Post-market: 13.97-0.0200-0.14%19:46 EDT

Volume:1.16M

Turnover:15.68M

Market Cap:1.79B

PE:-4.27

High:14.14

Open:13.50

Low:13.08

Close:13.57

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:0.98

T/O Rate:1.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:3.93

PE(LYR):-2.81

Loading ...

Overview Company News Filings

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline

Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)

Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x

Simply Wall St.

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

Simply Wall St.

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

MT Newswires Live

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

MT Newswires Live

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

THOMSON REUTERS

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/GENB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":13.99,"timestamp":1791489600000,"preClose":13.57,"halted":0,"volume":1155713,"hourTrading":{"tag":"盘后","latestPrice":13.97,"preClose":13.99,"latestTime":"19:46 EDT","volume":5244,"amount":73368.5107,"timestamp":1791503161901,"change":-0.02,"changeRate":-0.00143,"amplitude":0.00143},"delay":0,"changeRate":0.030950626381724387,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Closed","change":0.42,"latestTime":"10-08 16:00:00 EDT","open":13.5,"high":14.135,"low":13.08,"amount":15682862.454466999,"amplitude":0.077745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":5,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":13.57,"preHourTrading":{"tag":"盘前","latestPrice":13.44,"preClose":13.57,"latestTime":"08:53 EDT","volume":2231,"amount":30343.714988000003,"timestamp":1791463991008,"change":-0.13,"changeRate":-0.00958,"amplitude":0.112749},"postHourTrading":{"tag":"盘后","latestPrice":13.97,"preClose":13.99,"latestTime":"19:46 EDT","volume":5244,"amount":73368.5107,"timestamp":1791503161901,"change":-0.02,"changeRate":-0.00143,"amplitude":0.00143},"volumeRatio":0.983673,"impliedVol":0.8788,"impliedVolPercentile":0.6},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.983673,"shares":128192484,"dividePrice":0,"high":14.135,"amplitude":0.077745,"preClose":13.57,"low":13.08,"week52Low":11,"pbRate":"3.93","psRate":"67.72","week52High":22.6699,"institutionHeld":0,"latestPrice":13.99,"eps":-3.27625,"divideRate":0,"volume":1155713,"delay":0,"ttmEps":-3.27625,"open":13.5,"prevYearClose":16,"prevWeekClose":13.69,"prevMonthClose":15.02,"prevQuarterClose":15.02,"fiveDayClose":13.8,"twentyDayClose":15.39,"sixtyDayClose":14.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-10-07","current":-4.270126,"percent":0.875,"low":-11.002825,"twenty":-8.808739,"median":-8.067818,"eighty":-7.545823,"high":-6.883628,"avg":-8.206048,"sd":0.731868,"marketCap":1771263616},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-09-04","current":-8.821696,"twenty":-8.713719,"median":-7.99352,"eighty":-7.544963,"marketCap":2097278804},{"date":"2026-09-11","current":-8.308807,"twenty":-8.728836,"median":-8.030177,"eighty":-7.546682,"marketCap":1975343990},{"date":"2026-09-18","current":-9.242805,"twenty":-8.750431,"median":-8.056286,"eighty":-7.554594,"marketCap":2197393704},{"date":"2026-09-25","current":-8.632737,"twenty":-8.845636,"median":-8.06828,"eighty":-7.565666,"marketCap":2052355451},{"date":"2026-10-02","current":-7.450392,"twenty":-8.826331,"median":-8.077459,"eighty":-7.565666,"marketCap":1771263616},{"date":"2026-10-07","current":-7.450392,"twenty":-8.808739,"median":-8.067818,"eighty":-7.545823,"marketCap":1771263616}],"updateTime":1791505412932},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657638623","title":"Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638623","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638623?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"studies continue to advance. To date, the studies have received. regulatory approvals in 33 countries as part of a planned 42-country. development program. Additional approvals are ongoing, and recruitment is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682336","title":"Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682336","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682336?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:11","pubTimestamp":1786011111,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Q2 FY26 net loss widens to $67.26 million; revenue drops to $6.31 millionGenerate Biomedicines posted a GAAP net loss of $67.26 million for the quarter ended June 30, 2026, widen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8LfD7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0109394709.USD","LU0889565916.HKD","BK4533","IE00B2B36J28.USD","PBE","LU1571399168.USD","GENB","LU2468319806.SGD","LU2089984988.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4599","LU1983299246.USD","BK4534","BK4139","BK4588","IE0002141913.USD","BBH","IBB","BIB","LU2112291526.USD","AMGN","IBBQ","LU0289739699.SGD","BK4581","SG9999001440.SGD","PJP","TBXU","IE00BJT1NW94.SGD","LU2242652126.USD","BK4585","IE0009355771.USD","LU0868494617.USD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4566","LU1061106388.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647430327","title":"Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2647430327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647430327?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:47","pubTimestamp":1782748043,"startTime":"0","endTime":"0","summary":"Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipelineGenerate Biomedicines highlighted GB-0895, an anti-TSLP monoclonal antibody in Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9Yj1vn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646708218","title":"Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646708218","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646708218?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:50","pubTimestamp":1782388209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-yesway-inc-class-a-yswy-generate-biomedicines-inc-genb-and-sk-hynix-inc-sponsored-gdr-otherhxscl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-yesway-inc-class-a-yswy-generate-biomedicines-inc-genb-and-sk-hynix-inc-sponsored-gdr-otherhxscl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRAM","YSWY","SK","GENB","BK4113","RAM","BK4141","NA","EEMO","EMXC","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643127072","title":"Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643127072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643127072?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:08","pubTimestamp":1781521690,"startTime":"0","endTime":"0","summary":"In a report released today, Seamus Fernandez from Guggenheim maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $30.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952990","title":"Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952990?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:19","pubTimestamp":1780312753,"startTime":"0","endTime":"0","summary":"Stock performance snapshot\nGenerate Biomedicines (GENB) has drawn attention after recent trading, with the stock last closing at $13.12 and showing a mixed pattern over different periods, including a small move over the past month and a gain over the past 3 months.\nSee our latest analysis for Generate Biomedicines.\nRecent trading has been choppy, with a 7 day share price return of down 9.7% contrasting with a 90 day share price return of up 10.0%. This suggests short term momentum is cooling...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/assessing-generate-biomedicines-genb-valuation-as-losses-mou","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/assessing-generate-biomedicines-genb-valuation-as-losses-mou","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661666","title":"Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661666?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:14","pubTimestamp":1779999240,"startTime":"0","endTime":"0","summary":"Generate Biomedicines will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7ddLlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","IE00B19Z3581.USD","LU1868837136.USD","LU2237443978.SGD","LU2750360641.GBP","LU1668664300.SGD","LU0106831901.USD","BK4516","BK4585","LU2237443465.HKD","LU1868837300.USD","LU2237443549.SGD","IE0004086264.USD","LU0061475181.USD","LU2237443622.USD","BK4550","LU1791807156.HKD","LU1894683348.USD","IE0004091025.USD","LU1894683264.USD","LU2265009873.SGD","BK4533","GENB","BK4504","LU0251131958.USD","IE00B19Z3B42.SGD","LU1804176565.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU2471134523.USD","BK4552","BK4588","LU1868836757.USD","LU0868494617.USD","IE00BFXG1179.USD","LU0251142724.SGD","LU2750360997.AUD","LU2471134879.HKD","LU1868836591.USD","LU2237443895.HKD","IE0034235188.USD","LU2471134952.CNY","LU0868494708.USD","GSX","LU1868836914.USD","LU2471134796.USD","LU0345770308.USD","LU0096364046.USD","LU0742534661.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638542062","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2638542062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638542062?lang=en_us&edition=fundamental","pubTime":"2026-05-27 03:24","pubTimestamp":1779823440,"startTime":"0","endTime":"0","summary":"Generate Biomedicines highlighted GB-0895, a half-life extended anti-TSLP monoclonal antibody, with Phase 3 studies initiated for severe asthma.Program targets twice-yearly dosing via a single subcutaneous injection; femtomolar TSLP binding affinity of 106 fM, cited as 20x stronger than tezepelumab.Pipeline update flagged five computationally engineered clinical-stage or clinic-ready molecules; eight programs have reached candidate nomination.Cash balance totaled USD 221.5 million at year-end 2025; management framed a catalyst-heavy 12-24 month window led by GB-0895 readouts.Other near-term clinical starts include GB-4362 in metastatic urothelial cancer, GB-5267 in platinum-resistant ovarian cancer, both targeted for 1H26 initiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL4gbwpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117754821","title":"Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1117754821","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117754821?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:32","pubTimestamp":1779456750,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) experienced a significant intraday surge of 5.29% on Friday, drawing attention to the AI-focused biotech company.The stock movement follows Nvidia's recent $10.4 million...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637836082","title":"A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2637836082","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637836082?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:34","pubTimestamp":1779420874,"startTime":"0","endTime":"0","summary":"Nvidia’s recent US$10.4 million investment in Generate Biomedicines (GENB) has drawn fresh attention to the AI-focused biotech, as investors assess what this backing could mean for its drug development pipeline.\nSee our latest analysis for Generate Biomedicines.\nThe Nvidia investment comes after a volatile stretch for Generate Biomedicines, with a 1-day share price return of 7.37% to US$13.98, a 30-day share price return of 10.34% and a year to date share price return of 10.51%. This comes...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/a-look-at-generate-biomedicines-genb-valuation-after-nvidias","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/a-look-at-generate-biomedicines-genb-valuation-after-nvidias","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2168564495.EUR","LU1429558221.USD","LU0157215616.USD","LU1629891620.HKD","LU1064131342.USD","LU1935043023.USD","LU0094547139.USD","LU1232071149.USD","LU1914381329.SGD","LU2168564065.EUR","LU2381873111.SGD","SGXZ51526630.SGD","LU0289961442.SGD","LU0061474705.USD","NVD","LU1116320737.USD","NVDX","HK0000914660.USD","LU2430703095.HKD","LU0320765059.SGD","LU1366192091.USD","LU0345768740.USD","IE00B19Z8W00.USD","LU1923622291.USD","LU1633808545.USD","LU1989764664.SGD","LU1066051498.USD","LU1316542783.SGD","SG9999015341.SGD","IE00B5949003.HKD","SG9999004303.SGD","SG9999015978.USD","IE00BZ199S13.USD","NVDS.UK","LU2063271972.USD","IE00BMPRXR70.SGD","LU0724617625.USD","LU1551013342.USD","LU2083900584.USD","LU0256863902.USD","LU1815336760.USD","IE00B3SWFQ91.USD","LU2326559502.SGD","LU1244550577.SGD","3NVD.UK","LU1699723380.USD","LU2242650005.HKD","LU2433249047.HKD","LU2237957902.USD","LU2602419157.SGD","LU2125909916.SGD","LU0210533765.USD","LU1935042488.USD","LU0476273544.USD","LU1935043536.SGD","LU2361045086.USD","LU2106854487.HKD","NVDA","LU1791710400.SGD","LU2458330243.SGD","LU0342679015.USD","LU0861579265.USD","LU1670756490.USD","IE00BJTD4N35.SGD","LU2417539215.USD","LU1868837136.USD","LU2247934214.USD","IE0004445015.USD","SG9999000418.SGD","LU1983260115.SGD","LU1992135472.HKD","LU0198837287.USD","LU0077335932.USD","IE00B7KXQ091.USD","LU1066051225.USD","LU0211328371.USD","LU0889565833.HKD","07788","SG9999017495.SGD","IE00BZ1G4Q59.USD","LU0081259029.USD","LU0154236417.USD","LU0274383776.USD","LU2360032135.SGD","IE00B775SV38.USD","LU0210536198.USD","LU1691799644.USD","SG9999014542.SGD","SG9999014880.SGD","LU2322448791.USD","LU0683600562.USD","LU2249611893.SGD","LU2491050154.USD","LU0882574139.USD","LU1548497426.USD","IE00BHPRN162.USD","LU0057025933.USD","LU2213496289.HKD","LU2028103732.USD","SG9999015986.USD","LU0079474960.USD","LU0316494557.USD","LU0203202063.USD","LU1202635105.USD","IE00B4YYXB79.USD","LU0353189763.USD","LU1917777945.USD","LU2552382215.SGD","LU0719512351.SGD","LU2361044865.SGD","SG9999014898.SGD","LU2290526834.HKD","LU1868837300.USD","LU0985320562.USD","LU1951200564.SGD","LU2272731600.USD","LU0353189680.USD","IE00B4JS1V06.HKD","NVDW","GENB","SG9999014567.USD","LU0276348264.USD","LU0345770993.USD","LU2357125470.USD","NVDD","LU0466842654.USD","LU1804176565.USD","LU2168564149.EUR","LU2294711713.HKD","LU2089283258.USD","NVDS","BK4592","LU1674673428.USD","LU1992135399.USD","LU2461242641.AUD","LU2471134879.HKD","LU1066051811.HKD","LU1974910355.USD","SG9999001424.SGD","IE00B1BXHZ80.USD","BK4503","LU1496350171.SGD","LU0225283273.USD","IE00BWXC8680.SGD","IE0009356076.USD","LU2471134523.USD","LU2637965513.SGD","IE00BMPRXN33.USD","LU1069344957.HKD","LU1674673691.USD","IE00B3M56506.USD","LU2065171311.SGD","LU0056508442.USD","LU1267930573.SGD","LU0127658192.USD","LU2092627202.USD","LU2272731782.SGD","LU2244417387.USD","LU0472753341.HKD","LU2552382132.HKD","LU2999663052.SGD","LU2756315318.SGD","LU1551013425.SGD","LU0417517546.SGD","LU1821325948.USD","LU1868836914.USD","LU2746668974.SGD","LU0494093205.USD","BK4527","LU0097036916.USD","LU0979878070.USD","LU0011850046.USD","LU0965509010.AUD","LU0964807845.USD","LU1951198990.SGD","LU0323591593.USD","LU2458330169.SGD","IE00B3S45H60.SGD","LU0943347566.SGD","LU1496350502.SGD","LU0170899867.USD","LU1839511570.USD","BK4579","LU0957791311.USD","LU0128525929.USD","LU2505996509.AUD","LU0082616367.USD","LU2237438978.USD","LU2023250504.SGD","LU1923623000.USD","LU2463028550.USD","LU2191332357.HKD","LU1712237335.SGD","IE00BJJMRX11.SGD","IE00BQXX3C00.GBP","NVDQ","IE0004086264.USD","IE00BD6J9T35.USD","HK0000819398.USD","LU1852331112.SGD","LU2322448957.HKD","LU2125909759.SGD","NVD2.UK","IE00BQXX3F31.USD","IE00BDCRKT87.USD","LU0345769631.USD","BK4139","BK4614","LU0444971666.USD","LU2092937148.SGD","BK4598","LU1242518931.SGD","LU2236285917.USD","LU0109392836.USD","LU2087625088.SGD","LU0211327993.USD","LU2896262040.SGD","LU0289960550.SGD","LU0823414551.USD","LU0820561909.HKD","SG9999014906.USD","LU1934455277.USD","BK4548","LU0965508806.USD","LU0788109477.HKD","LU1066053197.SGD","LU2111349929.HKD","LU0238689110.USD","LU1934455863.HKD","LU1989772840.SGD","LU0048584097.USD","LU0672654240.SGD","LU0266013472.USD","IE0003U64NQ7.SGD","LU1803068979.SGD","SG9999014914.USD","BK4605","LU2125154935.USD","LU2250418816.HKD","IE0004445239.USD","LU2125154778.USD","LU0267386448.USD","BK4612","LU2047632596.USD","LU2592432038.USD","LU2054465674.USD","LU2491050071.SGD","BK4581","BK4551","LU1400636574.HKD","LU1267930730.SGD","HK0000914686.HKD","LU0823421333.USD","LU0234570918.USD","IE000W1ABFV2.USD","IE00B1XK9C88.USD","2NVD.UK","LU0345769128.USD","LU1145028129.USD","LU2089985449.USD","NVII","SG9999015952.SGD","LU2286300806.USD","SGXZ99366536.SGD","LU2462591277.SGD","LU2750360997.AUD","LU0310800379.SGD","LU0557290698.USD","LU0965509101.SGD","IE00BYXW3230.USD","LU0965509283.SGD","LU3102509885.SGD","ANV","LU2462591350.SGD","HK0000320223.HKD","LU0528227936.USD","LU2089284900.SGD","LU2487616109.SGD","GB00BDT5M118.USD","LU2271345857.HKD","LU1037948541.HKD","LU0124676726.USD","NVIW.SI","BK4529","LU1280957306.USD","LU1037948897.HKD","LU0511384066.AUD","BK4587","LU0006306889.USD","LU0158827948.USD","LU2087621335.USD","LU0203201768.USD","IE0004091025.USD","LU0080751232.USD","LU2552382058.USD","LU2860962120.EUR","SG9999002224.SGD","LU1935042991.SGD","LU0868494708.USD","LU0786609619.USD","LU0143551892.USD","IE0009G5SDU7.USD","IE00BN29S564.USD","IE0005OL40V9.USD","LU0215105999.USD","LU0289739343.SGD","LU0823414478.USD","LU1989772923.USD","SG9999014559.SGD","LU1989764748.USD","IE00BKPKM429.USD","LU1642822529.SGD","SG9999018857.SGD","LU1791710582.SGD","LU1778281490.HKD","BK4534","LU0106261372.USD","LU0096364046.USD","LU1267930490.SGD","LU1623119135.USD","LU2357305700.SGD","LU2543165471.USD","SG9999018865.SGD","LU0107464264.USD","SGXZ81514606.USD","LU0061475181.USD","LU0251132253.USD","BK4554","SG9999015945.SGD","LU0133085943.USD","LU1934455194.USD","LU2100268510.USD","IE0034235188.USD","LU2264538146.SGD","BK4550","LU0109391861.USD","IE00BK4W5L77.USD","LU0256863811.USD","BK4585","IE000KEQY171.SGD","LU0444973449.USD","LU0820561818.USD","LU1923622614.USD","LU2413666426.HKD","LU2452424414.USD","LU1127390331.HKD","LU0072462426.USD","IE00BQXX3D17.EUR","LU2065169927.USD","IE00BFSS7M15.SGD","BK4543","LU1366333091.USD","LU2954938101.SGD","LU0642271901.SGD","LU2931357623.SGD","BK4533","LU2237957811.SGD","LU1645745479.HKD","LU0787776722.HKD","LU1323610961.USD","LU0061474960.USD","BK4567","LU2471134796.USD","LU1400636491.USD","LU2077746001.SGD","SGXZ23171101.USD","LU2125909593.SGD","LU2430703251.USD","LU0070217475.USD","SG9999015358.SGD","LU2360106780.USD","LU0174119429.USD","LU2746668461.USD","LU1868836757.USD","LU0265550946.USD","IE0001KFT4U8.USD","LU0689472784.USD","LU1814569148.SGD","LU2394011477.USD","LU0308772762.SGD","LU0053666078.USD","LU0640476718.USD","LU2471134952.CNY","LU1084165304.USD","IE00B775H168.HKD","LU0823434583.USD","LU1988902786.USD","LU2211815571.USD","LU0234572021.USD","LU2462157665.USD","LU1035775433.USD","NVYY","LU0210528500.USD","LU0957808578.USD","LU2108987350.USD","LU2272731865.HKD","IE00BJJMRY28.SGD","LU1261432733.SGD","LU1119994496.HKD","LU1861127337.USD","LU1868836591.USD","LU0348723411.USD","NVDU","IE00BJLML261.HKD","LU0345768153.USD","LU1153585028.USD","LU0354030511.USD","LU0158827781.USD","LU2505996681.GBP","LU0820562030.AUD","LU1720051017.SGD","BK4608","07388","LU1116320901.HKD","LU2097344431.USD","HK0000306701.USD","HK0000320264.USD","IE00BKVL7J92.USD","LU2242649171.HKD","BK4532","LU2456880835.USD","LU0265550359.USD","LU2097344357.USD","LU2023250330.USD","IE0034235303.USD","LU0029864427.USD","LU1721428933.USD","LU2491049909.HKD","LU0823434740.USD","NVDB","LU0708995401.HKD","LU1571399168.USD","LU2420271590.USD","LU0175139822.USD","HK0000304805.HKD","LU2756315664.SGD","NVDO","IE00BKDWB100.SGD","IE000ITXATA3.USD","IE00B19Z9505.USD","LU1718418525.SGD","NVDY","LU2265009873.SGD","LU2360107168.USD","LU1815333072.USD","LU0069063385.USD","LU2750360641.GBP","LU2065171402.SGD","IE00BJTD4V19.USD","LU1935042215.USD","LU1244550221.USD","LU1244550494.USD","LU0708994859.HKD","IE00B19Z8X17.USD","BK4549","HK0000306685.HKD","IE00BFSS8Q28.SGD","IE00BDRTCR15.USD","LU2065170008.USD","LU0354030438.USD","DIPS","NVDL","LU2361044949.HKD","SNVD.UK","LU0187121727.USD","LU1400636657.SGD","HK0000532082.HKD","LU1861215975.USD","LU2506951792.HKD","LU0868494617.USD","LU0942090050.USD","LU2413666699.HKD","LU2168564222.USD","SGXZ31699556.SGD","LU0390134368.USD","LU0096362180.USD","LU0689626769.HKD","LU2023251221.USD","LU1720051108.HKD","BK4141","LU1861220033.SGD","LU0823421416.USD","LU1242518857.USD","IE0034235295.USD","LU2430703178.SGD","SG9999014575.USD","NVDG","LU1435385759.SGD","LU2473716301.USD","SG9999002232.USD","IE00BK4W5M84.HKD","HK0000304797.USD","LU2168563687.JPY","BK4588","NVD3.UK","LU0345770308.USD","LU0347712357.USD","LU2403377893.USD","LU2125909247.SGD","IE000YTNTUN2.SGD","LU0310799852.SGD","IE00BMPRXQ63.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009586","title":"U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009586?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:21","pubTimestamp":1779135660,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Monday, as the Russell 2000 Index declined 0.7%, while the S&P Small Cap 600 Index was up 0.3%.Among companies with a market value of $1 billion to $6.7 billion, Generate Biomedicines Inc. was the biggest laggard during the session, dropping 19%, followed by shares of Rackspace Technology Inc., which dropped 18%. Shares of FuelCell Energy Inc. dropped 17%, Aehr Test Systems shares plunged 16%, and Lightwave Logic Inc. plunged 15%.LiveRamp Holdings Inc. was the best performer, surging 27%, followed by T1 Energy Inc., which surged 23%. Genius Sports Ltd. shares surged 22%, Brady Corp. Cl A surged 19%, and shares of AEVEX Corp. Cl A surged 15%.Major stock indexes in the U.S. ended Monday mixed as the Nasdaq Composite Index fell 0.5%. Meanwhile, the S&P 500 Index fell 0.1%, and the Dow Jones Industrial Average added 0.3%.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742365","title":"Generate Biomedicines Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742365","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742365?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:25","pubTimestamp":1778779500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:25 ET (17:25 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749547","title":"Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635749547?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:16","pubTimestamp":1778771795,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $22.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/generate-biomedicines-inc-genb-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/generate-biomedicines-inc-genb-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1548497426.USD","LU1720051108.HKD","LU1989772923.USD","LU2133065610.SGD","LU2357305700.SGD","LU2028103732.USD","LU1791710400.SGD","LU0098860793.USD","LU1244550577.SGD","LU0912757837.SGD","BK4516","BK4127","LU1732800096.USD","LU0528227936.USD","LU0320765646.SGD","LU1162221912.USD","LU0158827781.USD","BK4139","LU0882574139.USD","GENB","LU1244550221.USD","LU1363072403.SGD","LU1791710582.SGD","LU2264538146.SGD","IE00BZ1G4Q59.USD","BK4581","LU1668664300.SGD","LU1074936037.SGD","LU1244550494.USD","LU0795875086.SGD","BK4534","LU2023251221.USD","LU0234570918.USD","LU2111349929.HKD","LU2089283258.USD","LU2089284900.SGD","LU2271345857.HKD","IE00BKVL7J92.USD","LU2347655156.SGD","LU0006306889.USD","LU1988902786.USD","LU0225283273.USD","LU0267386448.USD","LU0106261372.USD","BK4588","LU0390134368.USD","LU1989772840.SGD","BK4585","LU0795875169.SGD","LU0971096721.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719286","title":"Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719286","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719286?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:04","pubTimestamp":1778756658,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) has an average rating of buy and mean price target of $25.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633339451","title":"Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633339451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633339451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:59","pubTimestamp":1778245186,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Generate Biomedicines, Inc. today and set a price target of $24.00. Tenthoff cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945500","title":"Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945500?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:11","pubTimestamp":1778242260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 08:11 ET (12:11 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159146","title":"Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159146?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:16","pubTimestamp":1778152597,"startTime":"0","endTime":"0","summary":"“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” sa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111704","title":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633111704?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:22","pubTimestamp":1778149353,"startTime":"0","endTime":"0","summary":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633770117","title":"Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633770117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633770117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633707117","title":"Generate Biomedicines Inc - Q1 Revenue $7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633707117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633707117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}